Twist Bioscience Announces Clinical Progression Of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience Corporation (NASDAQ:TWST) announced the dosing of the first patient in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, an antibody discovered using Twist's antibody libraries. This study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors.
July 18, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience announced the dosing of the first patient in Pure Biologics' Phase 0 study of PBA-0405, an antibody discovered using Twist's libraries. This milestone could positively impact TWST's stock price in the short term.
The announcement of clinical progression using Twist's technology is a positive development, likely to boost investor confidence and potentially increase TWST's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100